HomeCompareSEPJF vs JNJ

SEPJF vs JNJ: Dividend Comparison 2026

SEPJF yields 2.17% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SEPJF wins by $7.7K in total portfolio value
10 years
SEPJF
SEPJF
● Live price
2.17%
Share price
$52.01
Annual div
$1.13
5Y div CAGR
28.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.0K
Annual income
$4,588.72
Full SEPJF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SEPJF vs JNJ

📍 SEPJF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSEPJFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SEPJF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SEPJF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SEPJF
Annual income on $10K today (after 15% tax)
$184.23/yr
After 10yr DRIP, annual income (after tax)
$3,900.41/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $85.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SEPJF + JNJ for your $10,000?

SEPJF: 50%JNJ: 50%
100% JNJ50/50100% SEPJF
Portfolio after 10yr
$34.1K
Annual income
$4,639.06/yr
Blended yield
13.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SEPJF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.5
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SEPJF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSEPJFJNJ
Forward yield2.17%2.13%
Annual dividend / share$1.13$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28.7%28%
Portfolio after 10y$38.0K$30.3K
Annual income after 10y$4,588.72$4,689.40
Total dividends collected$15.6K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SEPJF vs JNJ ($10,000, DRIP)

YearSEPJF PortfolioSEPJF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,979$278.94$10,592$272.30+$387.00SEPJF
2$12,116$368.36$11,289$357.73+$827.00SEPJF
3$13,453$488.94$12,123$472.89+$1.3KSEPJF
4$15,048$653.00$13,141$629.86+$1.9KSEPJF
5$16,979$878.54$14,408$846.81+$2.6KSEPJF
6$19,360$1,192.38$16,021$1,151.60+$3.3KSEPJF
7$22,351$1,635.30$18,122$1,588.22+$4.2KSEPJF
8$26,186$2,270.78$20,930$2,228.20+$5.3KSEPJF
9$31,219$3,199.98$24,792$3,191.91+$6.4KSEPJF
10$37,993$4,588.72$30,274$4,689.40+$7.7KSEPJF

SEPJF vs JNJ: Complete Analysis 2026

SEPJFStock

Spectris plc manufactures and sells measuring instruments and controls worldwide. It operates through Malvern Panalytical, HBK, Omega and Industrial Solutions segments. The Malvern Panalytical segment provides measurement and materials characterization and efficiency in R&D and manufacturing sectors. The HBK segment offers differentiated sensing, testing, modelling and simulation solutions for product development. The Omega segment provides process improvement, specialist sensors, and omni-channel distribution services. The Industrial Solutions segment operates high-value precision in-line sensing and monitors businesses. It also provides particle measuring systems, a solution to measure and monitor contamination levels in clean and controlled environments. In addition, the company offers red lion controls, an industrial automation tool that provides solutions to connect, monitor, and control disparate assets, as well as provides servomex, a specialist in gas and moisture analysis solutions. Further, it provides data and insights, test equipment and software for industrial applications. Additionally, the company offers sensor, instrument, software, and services technology, as well as provides training, technical support, spare parts, calibration, and maintenance services. It serves pharmaceutical, automotive, electronics, semiconductors, technology-LED, and primary and advanced materials industries. Spectris plc was incorporated in 1986 and is based in London, the United Kingdom.

Full SEPJF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SEPJF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SEPJF vs SCHDSEPJF vs JEPISEPJF vs OSEPJF vs KOSEPJF vs MAINSEPJF vs ABBVSEPJF vs MRKSEPJF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.